Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Citi
Merck
Harvard Business School
Farmers Insurance
AstraZeneca
Cerilliant
UBS
Deloitte
Colorcon
Argus Health

Generated: August 22, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Which drugs does patent 7,919,115 protect, and when does it expire?


Patent ► Subscribe protects LAMICTAL ODT and is included in one NDA. There has been one Paragraph IV challenge on Lamictal ODT.

This patent has seventeen patent family members in twelve countries.

Summary for Patent: ► Subscribe

Title:Orally disintegrating tablet compositions of lamotrigine
Abstract: The compositions of the present invention composition comprise a therapeutically effective amount of particles comprising lamotrigine, in combination with granules comprising a disintegrant, and a sugar alcohol and/or a saccharide. These compositions are useful in treating epilepsy and bipolar disorder, particularly for patients with dysphagia, and to improve compliance with bipolar patients.
Inventor(s): Venkatesh; Gopi M. (Vandalia, OH), Vyas; Nehal H. (Huber Heights, OH), Gosselin; Michael (Loveland, OH), Lai; Jin-Wang (Springboro, OH)
Assignee: Eurand, Inc. (Valdalia, OH)
Application Number:12/166,757
Patent Claim Types:
see list of patent claims
Formulation; Compound; Dosage form; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Glaxosmithkline Llc
LAMICTAL ODT
lamotrigine
TABLET, ORALLY DISINTEGRATING;ORAL022251-001May 8, 2009ABRXYesNo► Subscribe► SubscribeYY
Glaxosmithkline Llc
LAMICTAL ODT
lamotrigine
TABLET, ORALLY DISINTEGRATING;ORAL022251-002May 8, 2009ABRXYesYes► Subscribe► SubscribeYY
Glaxosmithkline Llc
LAMICTAL ODT
lamotrigine
TABLET, ORALLY DISINTEGRATING;ORAL022251-003May 8, 2009ABRXYesNo► Subscribe► SubscribeYY
Glaxosmithkline Llc
LAMICTAL ODT
lamotrigine
TABLET, ORALLY DISINTEGRATING;ORAL022251-004May 8, 2009ABRXYesNo► Subscribe► SubscribeYY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: ► Subscribe

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,647,656Orally disintegrating tablet compositions of lamotrigine► Subscribe
9,339,504Orally disintegrating tablet compositions of lamotrigine► Subscribe
8,840,925Orally disintegrating tablet compositions of lamotrigine► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: ► Subscribe

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina068185► Subscribe
Australia2008272871► Subscribe
BrazilPI0814408► Subscribe
Canada2693072► Subscribe
China101801192► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Citi
Teva
Medtronic
Moodys
Mallinckrodt
Fish and Richardson
Chubb
Cerilliant
Daiichi Sankyo
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot